COMMUNIQUÉS West-GlobeNewswire

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

31/01/2025 - 07:00

Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today. Conference call [...]

Communiqué de presse : Sarclisa est le premier anti-CD38 approuvé en Chine pour le traitement du myélome multiple nouvellement diagnostiqué des patients non éligibles à une greffe

31/01/2025 - 07:00

Sarclisa est le premier anti-CD38 approuvé en Chine pour le traitement du myélome multiple nouvellement diagnostiqué des patients non éligibles à une greffe Approbation motivée par les résultats positifs de l’étude de [...]

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

31/01/2025 - 07:00

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study that demonstrated [...]

Director/PDMR Shareholding

31/01/2025 - 08:00

DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support [...]

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

31/01/2025 - 11:50

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of [...]

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

31/01/2025 - 12:30

TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]

OKYO Pharma Announces Chairman and CEO Acquire Shares

31/01/2025 - 13:00

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), [...]

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

31/01/2025 - 13:00

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual [...]

SAB BIO to Participate in Upcoming Investor Conferences

31/01/2025 - 13:00

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti- [...]

23andMe Launches New Genetic Report on Osteoporosis

31/01/2025 - 13:30

Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME [...]

Quipt Home Medical Responds to Kanen Wealth Management

31/01/2025 - 13:30

Reaffirms commitment to enhancing shareholder value and strong corporate governance CINCINNATI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home [...]

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

31/01/2025 - 13:35

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

31/01/2025 - 14:00

— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch [...]

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

31/01/2025 - 14:00

DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced it has entered into a securities purchase agreement with a single institutional investor for [...]

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

31/01/2025 - 14:00

REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare [...]

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

31/01/2025 - 14:00

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]

Immutep Quarterly Activities Report Q2 FY25

31/01/2025 - 14:00

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT- [...]

Retrieve Medical Expands into Ambulatory Care with New Client Engagement

31/01/2025 - 14:00

BEDMINSTER, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Retrieve Medical, Inc. ( www.retrievemedical.com ) announces its expansion into the ambulatory care sector through a new client engagement with Saint Joseph’s Medical [...]

NewGen Announces Reverse Stock Split

31/01/2025 - 14:00

NewGen’s ordinary shares to begin trading on a split-adjusted basis on February 11, 2025 BANGKOK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive [...]